Cytokinetics (NASDAQ: CYTK) awards director 151 fully vested shares

Rhea-AI Filing Summary

Daly James M reported acquisition or exercise transactions in this Form 4 filing.

Cytokinetics Inc director James M. Daly received a grant of 151 shares of Common Stock on 2026-07-15 under the company’s Equity in lieu of Cash Retainer Program. The shares are fully vested at grant and increase his directly held position to 3,390 shares.

Insider Trade Summary

1 transaction reported

Mixed 1 txn

Insider Daly James M

Role Director

Type	Security	Shares	Price	Value
Grant/Award	Common Stock	151	$82.62	$12K

Holdings After Transaction: Common Stock — 3,390 shares (Direct)

Footnotes (1)

1. [object Object]

Key Figures

Shares granted: 151 shares Reported grant price: $82.62 per share Post-grant holdings: 3,390 shares

3 metrics

Shares granted 151 shares Non-derivative Common Stock grant to director on 2026-07-15

Reported grant price $82.62 per share Value per share for the 151-share Common Stock award

Post-grant holdings 3,390 shares Direct Common Stock beneficially owned by James M. Daly after the grant

Key Terms

Equity in lieu of Cash Retainer Program, fully vested, Common Stock

3 terms

Equity in lieu of Cash Retainer Program financial

"granted pursuant to the Cytokinetics Equity in lieu of Cash Retainer Program"

fully vested financial

"Shares are fully vested at the time of grant"

Common Stock financial

"Shares of common stock granted pursuant to the Cytokinetics Equity"

Common stock represents ownership shares in a company, giving investors a stake in its success and a say in important decisions through voting rights. It is the most common type of stock traded on markets and can provide income through dividends, as well as potential for value growth. For investors, holding common stock means sharing in the company’s profits and risks.

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

Form 4 Insider Transactions: What Each Field Means →

Available on EDGAR 07/16/2026 - 04:29 PM Accepted by SEC EDGAR 07/16/2026 - 04:28 PM Learn about SEC filing dates

FAQ

What insider transaction did Cytokinetics (CYTK) director James M. Daly report?

Director James M. Daly reported receiving a grant of 151 shares of Common Stock on 2026-07-15. The award was made as part of Cytokinetics’ Equity in lieu of Cash Retainer Program and represents compensation rather than an open-market share purchase.

At what price was the Cytokinetics (CYTK) director equity grant reported?

The 151-share grant to director James M. Daly was reported at $82.62 per share. This per-share figure reflects the value used for the non-derivative Common Stock award under Cytokinetics’ Equity in lieu of Cash Retainer Program on 2026-07-15.

How many Cytokinetics (CYTK) shares does James M. Daly hold after this grant?

Following the grant, James M. Daly directly holds 3,390 shares of Cytokinetics Common Stock. This total includes the newly granted 151 fully vested shares received under the company’s Equity in lieu of Cash Retainer Program for director compensation.

Was the Cytokinetics (CYTK) director grant an open-market purchase?

No. The 151 shares reported by director James M. Daly were granted as compensation under the Equity in lieu of Cash Retainer Program. The footnote explains the shares were issued instead of a cash retainer, not acquired through an open-market stock purchase.

Are the Cytokinetics (CYTK) shares granted to James M. Daly subject to vesting?

The 151 shares granted to James M. Daly are fully vested at the time of grant. According to the footnote, the Common Stock was issued under the Equity in lieu of Cash Retainer Program and is not subject to additional vesting conditions after the grant date.

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

Daly James M

(Last) (First) (Middle)

350 OYSTER POINT BLVD

(Street)

SOUTH SAN FRANCISCO CALIFORNIA 94580

(City) (State) (Zip)

UNITED STATES

(Country)

2. Issuer Name and Ticker or Trading Symbol
CYTOKINETICS INC [ CYTK ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

X	Director		10% Owner
	Officer (give title below)		Other (specify below)

2a. Foreign Trading Symbol

3. Date of Earliest Transaction (Month/Day/Year)
07/15/2026

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

4. If Amendment, Date of Original Filed (Month/Day/Year)

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price
Common Stock	07/15/2026		A(1)		151	A	$82.62	3,390	D

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares

Explanation of Responses:

1. Shares of common stock granted pursuant to the Cytokinetics Equity in lieu of Cash Retainer Program. Shares are fully vested at the time of grant.

	/s/ John O. Faurescu, attorney-in-fact for Mr. Daly	07/16/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.
* Form 4: SEC 1474 (03-26)